Publication Delays Impact Careers of Early-Career Researchers

By João L. Carapinha

May 19, 2025

The article “Dear editors, your publication delays are damaging our careers” by Chia-Hsuan Hsu highlights how publication delays hurt careers, especially for early-career researchers. With publication records key for jobs and tenure, slow editorial processes stall academic progress. The author shares waiting 18 months for a decision, blaming poor reviewer recruitment. This calls on editors to improve efficiency.

The Detrimental Impact of Delays

The article notes that publication delays impact careers by harming early-career researchers. Delays can cost job and funding chances, hindering growth. East Asia heavily weighs publication history in evaluations, making delays more damaging than in regions valuing broader contributions. Bottlenecks often stem from poor reviewer recruitment and communication, not scientific merit. While preprints speed up sharing findings, they often don’t count for career evaluations in Japan and Taiwan.

The article reflects broader issues in publishing and evaluation. The global academic system overvalues publications for hiring and funding, pressuring early-career researchers into a publish or perish culture. A few big publishers control the market while unpaid editorial labor leads to slow, profit-driven processes that clash with researchers’ needs. Delays often arise from reviewer shortages and overworked editors, hurting researchers needing timely output.

Proactive Solutions for a Changing Landscape

  • Reforming Academic Evaluation: Reports suggest valuing preprints and datasets more, but until reforms spread, early-career researchers suffer.
  • Innovative Peer Review Models: Open peer review and reviewer incentives could help, needing publisher and institutional cooperation.
  • Policy Recommendations: Health agencies and consortia could recognize preprints in evaluations, easing delays’ harm.

In summary, the article shows how publication delays hurt careers. Fixing this needs changes from editors, publishers, and institutions to ensure fair opportunities. For deeper insights, explore the source material.

Reference url

Recent Posts

Advancing Tarlatamab for Small Cell Lung Cancer Treatment

By HEOR Staff Writer

March 30, 2026

New Treatment Option for Relapsed Extensive-Stage Small Cell Lung Cancer Tarlatamab small cell lung therapy has received a positive opinion from the European Medicines Agency (EMA) for marketing authorisation. The bispecific T-cell engager is recommended as monotherapy ...
FDA Approves Once-Weekly Basal Insulin Awiqli® for Type 2 Diabetes Management
The US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) as the once-weekly basal insulin for adults with type 2 diabetes. This approval marks a major advancement in reducing treatment burden by decreasing basal insulin injections from seven to one per week.
Inflation Reduction Act Impact on Clinical Trial Investment Trends

By João L. Carapinha

March 26, 2026

The Inflation Reduction Act Impact is becoming evident in early data on industry-sponsored clinical trials. A recently published JME article examines how the Drug Price Negotiation Program (DPNP) introduced by the IRA may be altering investment incentives for biopharmaceutical innovation.